 Safety Data Help Establish Part B Dose Expansion and Phase 2 Dose; Data showed encouraging anti-tumor activity 4 PR out of 8 evaluable patients in NSCLC patients who failed prior PD1PDL1 therapies Safety Data Help Establish Part B Dose Expansion and Phase 2 Dose; Data showed encouraging anti-tumor activity 4 PR out of 8 evaluable patients in NSCLC patients who failed prior PD1PDL1 therapies 